- Margaret R. O’Donnell, MD,
- Martin S. Tallman, MD,
- Camille N. Abboud, MD,
- Jessica K. Altman, MD,
- Frederick R. Appelbaum, MD,
- Daniel A. Arber, MD,
- Vijaya Bhatt, MD,
- Dale Bixby, MD, PhD,
- William Blum, MD,
- Steven E. Coutre, MD,
- Marcos De Lima, MD,
- Amir T. Fathi, MD,
- Melanie Fiorella, MD,
- James M. Foran, MD,
- Steven D. Gore, MD,
- Aric C. Hall, MD,
- Patricia Kropf, MD,
- Jeffrey Lancet, MD,
- Lori J. Maness, MD,
- Guido Marcucci, MD,
- Michael G. Martin, MD,
- Joseph O. Moore, MD,
- Rebecca Olin, MD,
- Deniz Peker, MD,
- Daniel A. Pollyea, MD, MS,
- Keith Pratz, MD,
- Farhad Ravandi, MD,
- Paul J. Shami, MD,
- Richard M. Stone, MD,
- Stephen A. Strickland, MD, MSCI,
- Eunice S. Wang, MD,
- Matthew Wieduwilt, MD, PhD,
- Kristina Gregory, RN, MSN, OCN and
- Ndiya Ogba, PhD
Abstract
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
Footnotes
-
Please Note
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Acute Myeloid Leukemia are not printed in this issue of JNCCN but can be accessed online at NCCN.org.
© National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
-
Disclosures for the NCCN Acute Myeloid Leukemia Panel
At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.
Individual disclosures for the NCCN Acute Myeloid Leukemia Panel members can be found on page 957. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)
These guidelines are also available on the Internet. For the latest update, visit NCCN.org.
-
NCCN Acute Myeloid Leukemia Panel Members
*Margaret R. O’Donnell, MD/Chair‡ξ
City of Hope Comprehensive Cancer Center
*Martin S. Tallman, MD/Vice Chair‡
Memorial Sloan Kettering Cancer Center
Camille N. Abboud, MD‡Þξ
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Jessica K. Altman, MD‡
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Frederick R. Appelbaum, MD†Þξ
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Daniel A. Arber, MD≠
Stanford Cancer Institute
Vijaya Bhatt, MD‡
Fred & Pamela Buffett Cancer Center
Dale Bixby, MD, PhD‡†Þ
University of Michigan Comprehensive Cancer Center
William Blum, MD‡Þ†
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Steven E. Coutre, MD‡
Stanford Cancer Institute
Marcos De Lima, MD‡
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
Amir T. Fathi, MD‡†
Massachusetts General Hospital Cancer Center
Melanie Fiorella, MDÞ
UC San Diego Moores Cancer Center
James M. Foran, MD†
Mayo Clinic Cancer Center
Steven D. Gore, MD‡†
Yale Cancer Center/Smilow Cancer Hospital
Aric C. Hall, MD‡†
University of Wisconsin Carbone Cancer Center
Patricia Kropf, MD‡
Fox Chase Cancer Center
Jeffrey Lancet, MD‡†
Moffitt Cancer Center
Lori J. Maness, MD‡
Fred & Pamela Buffett Cancer Center
Guido Marcucci, MD†Þ
City of Hope Comprehensive Cancer Center
Michael G. Martin, MD†
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
Joseph O. Moore, MD†
Duke Cancer Institute
Rebecca Olin, MD‡
UCSF Helen Diller Family Comprehensive Cancer Center
Deniz Peker, MD≠
University of Alabama at Birmingham Comprehensive Cancer Center
Daniel A. Pollyea, MD, MS‡Þ†
University of Colorado Cancer Center
Keith Pratz, MD†
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Farhad Ravandi, MD‡
The University of Texas MD Anderson Cancer Center
Paul J. Shami, MD‡
Huntsman Cancer Institute at the University of Utah
Richard M. Stone, MD‡†
Dana-Farber/Brigham and Women’s Cancer Center
Stephen A. Strickland, MD, MSCI‡
Vanderbilt-Ingram Cancer Center
Eunice S. Wang, MD‡
Roswell Park Cancer Institute
Matthew Wieduwilt, MD, PhD‡ξ
UC San Diego Moores Cancer Center
NCCN Staff: Kristina Gregory, RN, MSN, OCN; and Ndiya Ogba, PhD
KEY:
*Discussion Section Writing Committee
Specialties: ‡Hematology/Hematology Oncology; ξBone Marrow Transplantation; ÞInternal Medicine; †Medical Oncology; ≠Pathology
- Copyright © 2017 by the National Comprehensive Cancer Network
